Hogan A M, Kirkham F J, Isaacs E B, Wade A M, Vargha-Khadem F
Developmental Cognitive Neuroscience Unit, Institute of Child Health, University College London and Great Ormond Street Hospital for Children, London, UK.
Dev Med Child Neurol. 2005 Dec;47(12):824-9. doi: 10.1017/S001216220500174X.
Intelligence is reported to decline after onset of moyamoya in Japanese populations, but there is less evidence for this in Western populations where the condition may be secondary to stroke and sickle cell anaemia (SCA). Preoperative longitudinal IQ data were obtained from 15 children (seven males, eight females) who developed moyamoya syndrome (MMS) following a stroke (six with SCA, nine without SCA), and 19 controls (10 males, nine females; nine healthy control participants, 10 with SCA). At baseline assessment (Time 1) median age of patients was 7 years 6 months (range 3y 7mo to 12y 5mo); median age of controls was 6 years 3 months (range 4y to 11y 6mo). At follow-up (Time 2), ages were 11 years 8 months (range 3y 7mo to 12y 5mo) and 12 years 8 months (range 6y 4mo to 16y 8mo) in patients and controls respectively. Median duration of follow-up for the patient group was 3 years (range 7 to 10y) and in controls, 4 years 1 month (range 1 to 10y). In children with SCA, Verbal and Performance IQs (VIQ and PIQ) were significantly lower than in controls at Time 1; there was an additional independent statistically significant reduction in PIQ associated with MMS (p=0.004). Although there were further significant reductions in IQ by the second assessment for patients with MMS compared with controls, IQ did not differ significantly between groups with and without SCA. While the reduction in IQ attributed to SCA does not appear to become more marked with increasing age, the difference between those with and without MMS is associated with increasing effect over time.
据报道,在日本人群中,烟雾病发病后智力会下降,但在西方人群中,这种情况的证据较少,在西方人群中,该病可能继发于中风和镰状细胞贫血(SCA)。术前纵向智商数据来自15名儿童(7名男性,8名女性),他们在中风后患上了烟雾病综合征(MMS)(6名患有SCA,9名没有SCA),以及19名对照者(10名男性,9名女性;9名健康对照参与者,10名患有SCA)。在基线评估(时间1)时,患者的中位年龄为7岁6个月(范围为3岁7个月至12岁5个月);对照者的中位年龄为6岁3个月(范围为4岁至11岁6个月)。在随访(时间2)时,患者和对照者的年龄分别为11岁8个月(范围为3岁7个月至12岁5个月)和12岁8个月(范围为6岁4个月至16岁8个月)。患者组的中位随访时间为3年(范围为7至10年),对照者为4年1个月(范围为1至10年)。在患有SCA的儿童中,语言智商和操作智商(VIQ和PIQ)在时间1时显著低于对照者;与MMS相关的PIQ还有额外的独立统计学显著降低(p=0.004)。尽管与对照者相比,MMS患者在第二次评估时智商进一步显著降低,但有SCA和没有SCA的组之间智商没有显著差异。虽然归因于SCA的智商降低似乎不会随着年龄增长而变得更加明显,但有MMS和没有MMS的人之间的差异与随着时间推移影响增加有关。